All In Biotech

Drug Trial Radar · NCT03492125

A Study Of The Selective PKC-β Inhibitor MS- 553

A Phase I/II Dose-Escalation and Expansion Study of the Selective PKC-β Inhibitor MS-553 in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Last checked: Nov 19, 2026Latest source record: Apr 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

60

Actual

Start

May 25, 2018

Primary completion

Nov 28, 2023

Study completion Nov 28, 2023

Sponsor

Lead sponsor
MingSight Pharmaceuticals, IncIndustry
Sponsor type
Industry
First posted
Apr 10, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase I/II Dose-Escalation and Expansion Study Of The Selective PKC-Β Inhibitor MS-553 In Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Conditions

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Aggressive Lymphoma

Interventions

  • MS-553Drug

    Oral, multiple dose levels

  • MS-553Drug

    Oral recommended phase 2 dose of MS-553

  • acalabrutinibDrug

    Oral

  • venetoclaxDrug

    Oral

  • RituximabDrug

    IV

  • obinutuzumabDrug

    IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Incidence Rate of DLT and TEAE Requiring Study Drug DiscontinuationTime frame: Assessments for DLT and TEAE will occur during Cycle 1 (28 days) for A1 Cohort and B1 Cohort and Cycles 1-4 (up to 112 days) for C1 Cohort.

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • University Of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan

  • Columbia University, Herbert Irving Comprehensive Cancer Center

    New York, New York

  • The Ohio State University, James Comprehensive Cancer Center

    Columbus, Ohio

  • MD Anderson Cancer Center, Department of Leukemia

    Houston, Texas

  • Huntsman Cancer Institute

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.